IGBA congratulates the Australian government for maintaining their biologics naming convention and for strengthening pharmacovigilance

January 29 2018 - The International Generic and Biosimilar medicines Association (IGBA) welcomes the Australian Government's decision to maintain the existing naming convention for biological, including biosimilar, medicines, that is to continue using the Australian biological name (without a specific identifier suffix) and to strengthen the adverse event reporting. This includes making the product's trade name, as well as the non-proprietary name, a mandatory field when reporting an adverse event to the Therapeutic Goods Administration (TGA).

IGBA welcomes new member Indian Pharmaceutical Alliance (IPA)!

2018-01-01 - The IGBA welcomes the Indian Pharmaceutical Alliance (IPA) to its membership. The IPA represents Indian research-based national pharmaceutical companies. This addition to the IGBA membership is significant in widening the IGBA representation, which now covers this important region.

The IGBA Biosimilars Committee has developed a communication slide deck on biosimilar medicines

2017-11-09 - If you wish to use any part of this slide deck, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.. We would be happy to share this with you.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mail: 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Follow us on: LinkedIn - YouTube